610 related articles for article (PubMed ID: 32966047)
21. Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation.
Gu L; Kong X; Li M; Chen R; Xu K; Li G; Qin Y; Wu L
Chem Commun (Camb); 2024 May; 60(42):5474-5485. PubMed ID: 38712400
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Engel AL; Holt GE; Lu H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
[TBL] [Abstract][Full Text] [Related]
23. Mechanical Immunoengineering of T cells for Therapeutic Applications.
Lei K; Kurum A; Tang L
Acc Chem Res; 2020 Dec; 53(12):2777-2790. PubMed ID: 33258577
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
25. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Caisová V; Uher O; Nedbalová P; Jochmanová I; Kvardová K; Masáková K; Krejčová G; Paďouková L; Chmelař J; Kopecký J; Ženka J
Int Immunopharmacol; 2018 Jun; 59():86-96. PubMed ID: 29635103
[TBL] [Abstract][Full Text] [Related]
26. Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists.
Jeong S; Choi Y; Kim K
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575449
[TBL] [Abstract][Full Text] [Related]
27. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
28. Engineering Strategies for Lymph Node Targeted Immune Activation.
Chen Y; De Koker S; De Geest BG
Acc Chem Res; 2020 Oct; 53(10):2055-2067. PubMed ID: 32910636
[TBL] [Abstract][Full Text] [Related]
29. Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of T cell responses.
Salem ML
Immunol Lett; 2011 Jun; 137(1-2):9-14. PubMed ID: 21352854
[TBL] [Abstract][Full Text] [Related]
30. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.
Lynn GM; Laga R; Darrah PA; Ishizuka AS; Balaci AJ; Dulcey AE; Pechar M; Pola R; Gerner MY; Yamamoto A; Buechler CR; Quinn KM; Smelkinson MG; Vanek O; Cawood R; Hills T; Vasalatiy O; Kastenmüller K; Francica JR; Stutts L; Tom JK; Ryu KA; Esser-Kahn AP; Etrych T; Fisher KD; Seymour LW; Seder RA
Nat Biotechnol; 2015 Nov; 33(11):1201-10. PubMed ID: 26501954
[TBL] [Abstract][Full Text] [Related]
31. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.
Zhou L; Zhang P; Wang H; Wang D; Li Y
Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102
[TBL] [Abstract][Full Text] [Related]
32. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.
Pahlavanneshan S; Sayadmanesh A; Ebrahimiyan H; Basiri M
J Immunol Res; 2021; 2021():9912188. PubMed ID: 34124272
[TBL] [Abstract][Full Text] [Related]
33. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
[TBL] [Abstract][Full Text] [Related]
34. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
Baxevanis CN; Voutsas IF; Tsitsilonis OE
Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
[TBL] [Abstract][Full Text] [Related]
35. Toll-like Receptor Agonist Conjugation: A Chemical Perspective.
Ignacio BJ; Albin TJ; Esser-Kahn AP; Verdoes M
Bioconjug Chem; 2018 Mar; 29(3):587-603. PubMed ID: 29378134
[TBL] [Abstract][Full Text] [Related]
36. Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands.
Klein JC; Wild CA; Lang S; Brandau S
Cancer Immunol Immunother; 2016 Jun; 65(6):689-700. PubMed ID: 27034235
[TBL] [Abstract][Full Text] [Related]
37. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
Xun Y; Yang H; Kaminska B; You H
J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891
[TBL] [Abstract][Full Text] [Related]
38. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.
Morse MA; Chapman R; Powderly J; Blackwell K; Keler T; Green J; Riggs R; He LZ; Ramakrishna V; Vitale L; Zhao B; Butler SA; Hobeika A; Osada T; Davis T; Clay T; Lyerly HK
Clin Cancer Res; 2011 Jul; 17(14):4844-53. PubMed ID: 21632857
[TBL] [Abstract][Full Text] [Related]
39. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
[TBL] [Abstract][Full Text] [Related]
40. An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases.
Liu Y; Li C; Xia H; Bi J; Guan R; Du X; Zhang H; He Z; Wang Y; Liu H
Acta Biomater; 2022 Mar; 141():132-139. PubMed ID: 35032721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
